Seres Therapeutics to Join Global Healthcare Conference
Seres Therapeutics, Inc. (Nasdaq: MCRB), a key player in the live biotherapeutics field, is preparing for an important presentation at the Cantor Global Healthcare Conference. This event will serve as a prime opportunity to share insights and showcase the Company’s progress in innovative therapies.
Presentation by Leadership Set
On September 18, Eric Shaff, the President and CEO of Seres, will present at 3:05 p.m. ET. The Company invites anyone interested to tune in. A video webcast of the presentation will be accessible in the “Events and Presentations” section of Seres' official website.
How to Access the Event
If you can’t make it to the live presentation, don’t worry—a replay will be available about an hour after the event ends. This replay will be kept archived for 21 days, giving everyone a chance to catch up on the significant information shared during the conference.
About Seres Therapeutics
Seres Therapeutics is dedicated to revolutionizing patient care, particularly for medically vulnerable populations. The Company is focused on developing innovative live biotherapeutics aimed at improving health outcomes. Notably, they celebrate VOWST™, recognized as the first FDA-approved orally administered microbiome therapeutic.
New Therapeutics Under Development
Seres is currently working on SER-155, an innovative therapeutic designed to prevent bloodstream infections that stem from gastrointestinal issues. This initiative reflects the Company’s commitment to enhancing patient safety by strengthening epithelial barriers and promoting immune tolerance to reduce complications such as graft-versus-host disease.
Support for Vulnerable Populations
In addition to SER-155, Seres is developing various cultivated oral live biotherapeutics to meet the needs of medically vulnerable individuals. Their efforts are geared towards providing therapeutic solutions for those affected by chronic liver disease, cancer-related neutropenia, and patients needing solid organ transplants. The Company remains focused on enhancing patient outcomes through scientific innovation.
Engaging with Investors
In their commitment to transparency, Seres welcomes inquiries from investors and media representatives. Interested stakeholders can reach out using the provided contact information for any questions or further information regarding their therapeutic advancements.
Frequently Asked Questions
What event is Seres Therapeutics participating in?
Seres Therapeutics will be part of the Cantor Global Healthcare Conference.
When is the Seres presentation taking place?
The presentation is set for September 18, starting at 3:05 p.m. ET.
How can I view the presentation?
Individuals interested in the presentation can access the webcast on the Seres website.
What does VOWST™ refer to?
VOWST™ is the first microbiome therapeutic that has been approved by the FDA for oral administration, developed by Seres Therapeutics.
What is the purpose of SER-155?
SER-155 is a developing therapeutic aimed at preventing severe infections and bolstering immune responses in patients.